Satellos Bioscience (TSE:MSCL)
TSX:MSCL
Want to see TSE:MSCL full AI Analyst Report?
MSCL Stock Chart & Stats
C$11.91
C$0.01(1.16%)
At close: 4:00 PM EST
C$11.91
C$0.01(1.16%)
Day’s Range― - ―
52-Week RangeC$6.24 - C$18.98
Previous CloseN/A
Volume29.01K
Average Volume (3M)178.54K
Market Cap
C$172.90M
Enterprise ValueC$41.10M
Total Cash (Recent Filing)C$69.96M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Aug 31, 2026EPS Estimate
-0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.96
Shares Outstanding20,831,190
10 Day Avg. Volume239,110
30 Day Avg. Volume178,539
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)3.04
Price to Sales (P/S)0.00
P/FCF Ratio-3.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$28.65Price Target Upside140.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.88
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free balance sheet meaningfully reduces interest burden and leverage risk for a pre-revenue biotech. This structural strength gives management flexibility to time equity or partnership financings, preserves future cash flow from interest payments, and improves resilience during long development cycles.
Focused Pipeline In Skeletal Muscle DiseasesA narrow, disease-focused R&D strategy concentrates expertise and resources on high-unmet-need indications like Duchenne. That specialization can raise scientific depth, enable targeted clinical designs, increase odds for orphan incentives, and make the company a clearer partner or acquisition target over the medium term.
Improving FCF Trend In TTMAn improvement in trailing-twelve-month free cash flow versus the prior year signals early progress in cash management or program pacing. If sustained, this trend can extend runway, reduce near-term financing pressure, and reflect operational discipline in R&D spending—important over the next several quarters.
Bears Say
Pre-revenue Business ModelOperating with no product revenue leaves the company fully dependent on external capital to fund R&D and operations. Over a multi-quarter horizon this increases execution risk: failure to secure financing or advance trials can halt development and jeopardize value creation for investors.
Large And Persistent Cash BurnSustained TTM losses and deeply negative free cash flow materially raise the likelihood of near-term fundraising. Repeated capital raises can dilute equity and shift strategic control, while high burn magnifies pressure to find partnership or licensing deals before clinical proof points are achieved.
Equity Volatility / Capital ActivitySharp swings in shareholders' equity typically reflect dilutive financings or accounting impacts from capital transactions. Recurring material capital activity signals dependence on external funding, which can erode existing holders' stakes and increase uncertainty about long-term shareholder value retention.
Satellos Bioscience News
MSCL FAQ
What was Satellos Bioscience’s price range in the past 12 months?
Satellos Bioscience lowest stock price was C$6.24 and its highest was C$18.98 in the past 12 months.
What is Satellos Bioscience’s market cap?
Satellos Bioscience’s market cap is C$172.90M.
When is Satellos Bioscience’s upcoming earnings report date?
Satellos Bioscience’s upcoming earnings report date is Aug 31, 2026 which is in 86 days.
How were Satellos Bioscience’s earnings last quarter?
Satellos Bioscience released its earnings results on May 15, 2026. The company reported -C$0.729 earnings per share for the quarter, missing the consensus estimate of -C$0.675 by -C$0.054.
Is Satellos Bioscience overvalued?
According to Wall Street analysts Satellos Bioscience’s price is currently Undervalued.
Does Satellos Bioscience pay dividends?
Satellos Bioscience does not currently pay dividends.
What is Satellos Bioscience’s EPS estimate?
Satellos Bioscience’s EPS estimate is -0.71.
How many shares outstanding does Satellos Bioscience have?
Satellos Bioscience has 20,831,190 shares outstanding.
What happened to Satellos Bioscience’s price movement after its last earnings report?
Satellos Bioscience reported an EPS of -C$0.729 in its last earnings report, missing expectations of -C$0.675. Following the earnings report the stock price went down -0.201%.
Which hedge fund is a major shareholder of Satellos Bioscience?
Currently, no hedge funds are holding shares in TSE:MSCL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Satellos Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$28.65 (140.53% Upside)
C$28.65 (140.53% Upside)
Blogger Sentiment
Bullish
TSE:MSCL Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth C$251.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-20.16%
12-Months-Change
Fundamentals
Return on Equity
-51.42%
Trailing 12-Months
Asset Growth
69.55%
Trailing 12-Months
Company Description
Satellos Bioscience
Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of Duchenne. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
MSCL Stock 12 Month Forecast
Average Price Target
C$28.65
▲(140.53% Upside)
Technical Analysis
Arch Biopartners
―
Medicenna Therapeutics Corp
―
Helix BioPharma
―
ME Therapeutics Holdings, Inc.
―
Onco-Innovations Ltd.
―
Options Prices
Currently, No data available
---